Last reviewed · How we verify

GSK Biologicals' DTPa-IPV/Hib vaccine

GlaxoSmithKline · Phase 3 active Biologic

GSK Biologicals' DTPa-IPV/Hib vaccine is a Inactivated combination vaccine Biologic drug developed by GlaxoSmithKline. It is currently in Phase 3 development for Primary immunization against diphtheria, tetanus, pertussis, poliomyelitis, and Haemophilus influenzae type b in infants and children.

This combination vaccine stimulates the immune system to produce antibodies and cellular immunity against diphtheria, tetanus, pertussis, poliomyelitis, and Haemophilus influenzae type b.

This combination vaccine stimulates the immune system to produce antibodies and cellular immunity against diphtheria, tetanus, pertussis, poliomyelitis, and Haemophilus influenzae type b. Used for Primary immunization against diphtheria, tetanus, pertussis, poliomyelitis, and Haemophilus influenzae type b in infants and children.

At a glance

Generic nameGSK Biologicals' DTPa-IPV/Hib vaccine
SponsorGlaxoSmithKline
Drug classInactivated combination vaccine
ModalityBiologic
Therapeutic areaImmunology / Infectious Disease Prevention
PhasePhase 3

Mechanism of action

DTPa-IPV/Hib is a pentavalent inactivated vaccine containing antigens from five pathogens. The diphtheria and tetanus components are toxoids (inactivated toxins), the acellular pertussis component contains purified bacterial antigens, the IPV component contains inactivated poliovirus strains, and the Hib component contains conjugated polysaccharide. Together, these antigens trigger both humoral and cell-mediated immune responses to provide protection against these infectious diseases.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about GSK Biologicals' DTPa-IPV/Hib vaccine

What is GSK Biologicals' DTPa-IPV/Hib vaccine?

GSK Biologicals' DTPa-IPV/Hib vaccine is a Inactivated combination vaccine drug developed by GlaxoSmithKline, indicated for Primary immunization against diphtheria, tetanus, pertussis, poliomyelitis, and Haemophilus influenzae type b in infants and children.

How does GSK Biologicals' DTPa-IPV/Hib vaccine work?

This combination vaccine stimulates the immune system to produce antibodies and cellular immunity against diphtheria, tetanus, pertussis, poliomyelitis, and Haemophilus influenzae type b.

What is GSK Biologicals' DTPa-IPV/Hib vaccine used for?

GSK Biologicals' DTPa-IPV/Hib vaccine is indicated for Primary immunization against diphtheria, tetanus, pertussis, poliomyelitis, and Haemophilus influenzae type b in infants and children.

Who makes GSK Biologicals' DTPa-IPV/Hib vaccine?

GSK Biologicals' DTPa-IPV/Hib vaccine is developed by GlaxoSmithKline (see full GlaxoSmithKline pipeline at /company/gsk).

What drug class is GSK Biologicals' DTPa-IPV/Hib vaccine in?

GSK Biologicals' DTPa-IPV/Hib vaccine belongs to the Inactivated combination vaccine class. See all Inactivated combination vaccine drugs at /class/inactivated-combination-vaccine.

What development phase is GSK Biologicals' DTPa-IPV/Hib vaccine in?

GSK Biologicals' DTPa-IPV/Hib vaccine is in Phase 3.

What are the side effects of GSK Biologicals' DTPa-IPV/Hib vaccine?

Common side effects of GSK Biologicals' DTPa-IPV/Hib vaccine include Injection site reactions (pain, redness, swelling), Fever, Irritability, Drowsiness, Loss of appetite.

Related